Ironwood lifts full-year outlook on LINZESS growth, posting $59.8m quarterly profit

Ironwood Pharmaceuticals reported a GAAP net income of $59.8 million on revenue of $133.0 million for the quarter ended September, and used the 5 November results to upgrade its financial forecasts for 2026. The company attributed the move to growth in LINZESS (linaclotide), its medicine for irritable bowel syndrome and constipation.

Ironwood now expects US net sales of LINZESS to land between $1.20 billion and $1.25 billion this year. Separately, it guides to total company revenue of $485 million to $510 million. The summary of the results does not explain how the two measures relate, and it does not give the earlier ranges, so the size of the increase cannot be stated here.

On the pipeline, Ironwood said the confirmatory Phase 3 STARS-2 study of apraglutide in short bowel syndrome with intestinal failure is under way. The company reported that every international clinical trial application it planned has been filed, and that each is either being reviewed or has been approved.

No details were provided on STARS-2 timing, patient enrolment or when data might be reported, and none should be inferred. Whether the study's international sites can open will depend on the outcome of those regulatory reviews.